在欧洲对患有 Omega-3 脂肪酸的精神病超高风险受试者进行安慰剂对照试验 (PURPOSE)
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
研究概览
详细说明
PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in conducted at 14 sites in 9 countries.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Petah Tikva、以色列
- Schneider Children's Medical Center
-
Ramat Gan、以色列
- Tel Hashomer The Sheba Medical Center
-
-
-
-
-
Vienna、奥地利
- BioPsyC Biopsychosocial Corporation
-
-
-
-
-
Tübingen、德国
- Department of Child and Adolescent Psychiatry, University of Tübingen
-
-
-
-
-
Rome、意大利
- Fondazione Santa Lucia
-
Rome、意大利
- Sapienza University of Rome
-
-
-
-
-
Bergen、挪威
- Institute of Clinical Medicine, University of Bergen
-
-
-
-
-
Zurich、瑞士
- ZKJP University Zürich
-
-
-
-
-
Edinburgh、英国
- Psychiatry, Centre for Clinical Brain Sciences
-
-
-
-
-
Utrecht、荷兰
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht
-
-
-
-
-
Barcelona、西班牙
- Hospital Clinic de Barcelona
-
Barcelona、西班牙
- Hospital Infantil Passeig Sant Joan de Deu
-
Madrid、西班牙
- Hospital General Universitario Gregorio Marañon
-
Santander、西班牙
- Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written informed consent of the subject. For individuals younger than 18 years of age the parents / legal representatives need to give consent, and the subject can provide assent (whether the latter is required depends on local laws and regulations).
- UHR diagnosis as made using the Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005). Subjects have to meet one or more of the following criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic symptoms (a history of one or more episodes of frank psychotic symptoms that resolved spontaneously within 1 week in the past year), or (c) either the presence of schizotypal personality disorder or a family history of psychosis in a first-degree relative, all three together with a recent decline in function.
Exclusion Criteria:
- Any clinically significant medical condition that may influence the results of the trial or affect the ability to take part in a trial.
- Laboratory screening values considered clinically relevant by a medical doctor for transaminases, thyroid hormones or coagulation parameters
- Current or past DSM-IV diagnosis of psychosis, as measured with K-SADS-PL
- Current treatment with an antipsychotic or mood-stabilising agent
- Intake of an antipsychotic or mood-stabilising agent in the two weeks prior to study inclusion
- Intake of an antipsychotic agent equivalent to a total haloperidol use of >50 mg in the six months prior to study inclusion
- A first-degree relative (i.e. parents, offspring or siblings) participating in this study
- UHR diagnosis on the basis of attenuated psychotic symptoms that are entirely explained by acute intoxication
- Current aggression or dangerous behaviour (PANSS G14 score 5 or above)
- Current suicidality / self-harm (PANSS G6 score 7)
- Current DSM-IV diagnosis of alcohol or substance dependence as measured with K-SADS-PL
- Any current or previous neurological disorder, including epilepsy
- History of head injury resulting in unconsciousness lasting at least 1 hour
- IQ < 70
- More than 4 weeks of regular omega-3 supplementation (>2 daily capsules standard strength providing >600 mg combined EPA/DHA) within the last 6 months.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Omega-3 fatty acids
Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months. |
其他名称:
|
|
安慰剂比较:Placebo
Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Transition Rate
大体时间:measured starting from baseline up to 2 years post-baseline
|
To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition). |
measured starting from baseline up to 2 years post-baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Discontinuation Rate
大体时间:measurement starting at baseline up to 2 years post-baseline
|
how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline) |
measurement starting at baseline up to 2 years post-baseline
|
|
Symptomatology
大体时间:baseline to 2 years post-baseline
|
change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms. |
baseline to 2 years post-baseline
|
|
Psychosocial Functioning
大体时间:measurement started at baseline up to the 2 year timepoint
|
Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning. |
measurement started at baseline up to the 2 year timepoint
|
|
Intelligence
大体时间:One time assessment of IQ
|
This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning |
One time assessment of IQ
|
|
Blood Levels of Bioactive Lipids
大体时间:measurement started at baseline up until 6 months
|
Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline. |
measurement started at baseline up until 6 months
|
|
Positive and Negative Symptoms
大体时间:from baseline to 2 years post-baseline
|
Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms. |
from baseline to 2 years post-baseline
|
|
Level of Functioning
大体时间:from baseline to 2 years post-baseline
|
Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning. |
from baseline to 2 years post-baseline
|
|
Level of Depression
大体时间:measured starting at baseline up to 2 years post-baseline
|
Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms. |
measured starting at baseline up to 2 years post-baseline
|
|
Role Functioning
大体时间:measurement started at baseline up until 2 years post-baseline
|
Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction. |
measurement started at baseline up until 2 years post-baseline
|
|
Social Functioning
大体时间:measurement started at baseline up until 2 years post-baseline
|
Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation. |
measurement started at baseline up until 2 years post-baseline
|
合作者和调查者
赞助
调查人员
- 学习椅:René Kahn, Prof. Dr.、UMC Utrecht
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.